Pharmacologic treatments for covid-19 patients

Baricitinib vs Standard care/Placebo


Hospitalized patients

Forest plots
(last update: 2022-10-07)

Summary of findings
(last update: 2022-10-13)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=382

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04891133; EudraCT 2021-000541-41; EU CTIS 2022-500385-99-00
Bari-SolidAct
Troseid M, SSRN, 2022
Full text
Commentary
Commentary
Mixed

Baricitinib

Placebo

RCT Patients with confirmed COVID-19 (severe-critical) admitted to 39 centers in Austria, Belgium, France, Ireland, Italy, Luxembourg, Norway, Portugal and Spain. N=284
Some concerns
Details

Full description

NCT04381936; EudraCT2020-001113-21; ISRCTN50189673
RECOVERY
Horby P, Lancet, 2022 b
Full text
Full text
Commentary
Commentary
Commentary
Public/non profit

Baricitinib

Standard care

RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 159 centers in the UK. N=8156
Some concerns
Details

Full description

NCT04421027
COV-BARRIER
Ely EW, Lancet Respir Med, 2022
Full text
Full text
Commentary
Commentary
Commentary
Private

Baricitinib

Placebo

RCT Patients with confirmed COVID-19 (critical) admitted to 18 centers in Argentina, Brazil, Mexico and USA. N=101
Low
Details

Full description

NCT04421027
COV-BARRIER
Marconi V, Lancet Respir Med, 2021
Full text
Full text
Full text
Commentary
Commentary
Private

Baricitinib

Placebo

RCT Patients with confirmed COVID-19 (mild-moderate-severe) admitted to 101 centers in Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, UK, USA N=1525
Some concerns
Details

Full description